Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Actinium-225 conjugated to daratumumab

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Actinium

Drug class:

Ionizing radiation emitter, CD38-targeted antibody-drug conjugate

Related drugs:

‹

›

CD38 positive	Multiple Myeloma	CD38 positive	Multiple Myeloma	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D
CD38 positive	Burkitt Lymphoma	CD38 positive	Burkitt Lymphoma	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D	Actinium-225 conjugated to daratumumab Sensitive: D – Preclinical Actinium-225 conjugated to daratumumab Sensitive : D